Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
Open Posted
- Opportunity number
- PAR-25-104
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
-
- 93.399 Cancer Control
- Funding instrument
- Grant
- Categories
-
- Health
- Education
- Eligible applicants
-
- Tribal Organizations (Not Federally Recognized)
- Higher Education Inst. (Public)
- Tribal Governments (Federally Recognized)
- Small Businesses
- Other
- For Profit Organizations
- Special District Governments
- 501(c)(3) Nonprofits
- Higher Education Inst. (Private)
- Public or Indian Housing Auth.
- County Governments
- State Governments
- Non-501(c)(3) Nonprofits
- Independent School Districts
- City/Township Governments
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health is soliciting applications for the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) to fund preparatory studies that address information gaps and feasibility unknowns before full-scale clinical trial launch, with applications due October 25, 2027.
Eligible applicants include state and local governments, tribal governments (federally and non-federally recognized), higher education institutions (public and private), 501(c)(3) and non-501(c)(3) nonprofits, small businesses, for-profit organizations, faith-based or community-based organizations, HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, AANAPISIs, TCCUs, regional organizations, eligible federal agencies, U.S. territories and possessions, and non-domestic entities.
This opportunity funds planning and feasibility work across the cancer prevention and control spectrum, including prevention and interception, cancer-related health behaviors, screening and early detection, healthcare delivery, treatment-related symptom management, supportive care, and long-term survivor outcomes. Preparatory studies should identify and fill critical information gaps about the study population, accrual challenges, intervention design, outcome endpoints, data and statistical challenges, or operational risks that would otherwise necessitate protocol changes and cost overruns during trial execution. The program also welcomes testing of new trial designs that minimize infrastructure requirements and reduce operational costs.
Evaluation criteria assess scientific merit and significance, technical adequacy of experimental design, investigator competency, adequacy of facilities and resources, budget necessity, and relevance to announced program objectives. Applications are reviewed by scientific peer review and the National Cancer Advisory Board.
The funding opportunity is assigned to Assistance Listing 93.399 (Cancer Control), which has supported 2,228 awards totaling $4.85 billion since 1983. Award size and number of awards are not specified in this announcement.
Synopsis
The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Files
| File | Type | Posted |
|---|---|---|
| PAR-25-104-Full-Announcement.html | HTML file | |
| PKG00288474.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity